ONE BREAKTHROUGH COULD CHANGE EVERYTHING.
One Pill, Multiple Life Changing Opportunities.
Only 1 in 5,000 drugs reach clinical trials. Trethera is already there.
Unmatched Expertise Driving Drug Breakthroughs
Starting from a drug discovered by renowned UCLA scientists, Trethera advances transformative therapies leveraging years of experience in research and development.
Innovating the Future of Cancer and Autoimmune Therapies
We’re pioneering a pipeline of innovative therapies, blending rigorous science with a patient-centered approach to create first-in-class treatments.
One Pill, One Solution,
Multiple Implications.
Introducing TRE-515 – A groundbreaking, well tolerated, therapy targeting multiple diseases.
Many patients with cancer and autoimmune diseases face limited treatment options with severe side effects. TRE-515 is designed to potentially offer a safer, more effective solution, targeting diseases at their root.
Trethera News & Publications
Los Angeles, January 15, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the Crohn’s & Colitis...
Los Angeles, July 16, 2024 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million NIH Small Business Innovation Research...
Los Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, received a unanimous recommendation from the independent safety review...